Ремиссии при шизофрении: результаты популяционного и фармакотерапевтического исследований
Потапов Андрей Владимирович, Дедюрина Юлия Михайловна, Ушаков Юрий Владимирович et al. · Социальная и клиническая психиатрия · 2010
This study involved two districts of a Moscow psychoneurological dispensary. The first stage of investigation consisted in determining cross-section remission rates for patients diagnosed as cases of schizophrenia and schizoaffective disorders, according to international criteria for the ICD-10. During a 6-month follow-up the researchers observed if remissions met the accepted time criteria. At the second stage of investigation, stable patients that did not meet the remission criteria, in one district started receiving Risperidone Prolong while in another district (control group) they went on with standard antipsychotic treatment. Cross-section analysis showed that of 203 patients 64 (31.5%) met the symptomatic criteria, and 53 (26.1%) of them maintained the remission during 6 months. 139 (68.5%) patients did not meet the symptomatic criteria for remission, and 105 (51.7%) remained stable during follow-up observation. At the second stage, 42 stable patients that did not meet the criteria for remission started receiving Risperidone Prolong, and 35 patients in another district formed a control group. In the first group, 19.0% patients achieved remission while in the second group only 5.7%. Besides, patients in the first group showed more significant reduction of symptoms on PANSS and improvement in social and everyday life functioning on PSP. The differences on these parameters were statistically significant.
Cited by 0 works.